---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-003765"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T21:53:27.715519+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q2 rev $12.6M (+9.6% YoY); net income $0.1M vs loss

## Summary
- Revenue $12.6M for Q2 ended Dec 31, 2024, up from $11.5M a year ago; six-month rev $26.2M (+7.4%).
- Operating income $0.2M vs operating loss $0.5M in prior year quarter; six-month op income $0.7M.
- Net income $0.1M ($0.00 EPS) vs net loss $0.4M ($(0.01) EPS) in prior year quarter.
- Two largest contract manufacturing customers represented ~82% of total revenue in the six-month period.
- Co-CEOs cite customer base expansion and core business focus as drivers of revenue growth.

## SEC filing metadata
- accession: 0001437749-25-003765
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774925003765/0001437749-25-003765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774925003765/inbp20250211_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-003765
- JSON: https://secwatch.observer/filing/0001437749-25-003765.json
- Plain text: https://secwatch.observer/filing/0001437749-25-003765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.